Seraxis Announced Closing of $40M Series C Financing Round

GERMANTOWN, Md., Feb. 9, 2021 /PRNewswire/ — Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes today announced the successful closing of a $40M Series C private financing round. The financing was led by Eli Lilly and Company, with…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.